Ligand Pharmaceuticals stock gains 2.33% as annual Investor Day event set for December, Ligand Pharmaceuticals Incorporated

Traders Union
All News
Companies
Ligand Pharmaceuticals up 2.33% today

Highlights

LGND maintains a strong bullish structure, currently trading well above key support levels across all major timeframes.
Momentum remains elevated, but overbought indicators suggest the rally is stretched with limited signs of profit-taking so far.
Next week, the expected trading range is $233.00–$256.00, with resistance at $247.38 and breakout potential if bullish momentum persists.

Bullish structure reinforced as price holds above key moving averages

LGND is trading at $243.28, well above the SMA-20 ($227.45), SMA-50 ($222.80), and SMA-200 ($197.99), which confirms a strong bullish structure for the short, medium, and long term. The Ichimoku Kijun on D1 sits at $222.01, serving as immediate support; near-term supports are clustered at the SMA-20 ($227.45) and Kijun ($222.01), while key support is seen at the SMA-50 ($222.80); near-term resistance is at the weekly high ($244.01), with key resistance defined by the 52-week high at $247.38.

Rally stretched as mixed momentum signals meet resistance approach

Momentum remains strong, with MACD and ADX both indicating ongoing buying pressure, though ADX D1 is neutral, suggesting the trend may be maturing. RSI (65.78) is extended but not extreme, while Stoch RSI and CCI both flag clear overbought conditions, signaling the rally is stretched. BBP confirms dominant buyer control, and the Awesome Oscillator supports the bullish trend. In today's session, LGND advanced 2.33%, signaling robust intraday momentum. Over the past week, the stock has risen $6.28 (2.65%) from a prev_week_close of $237.00, now standing at the top of its weekly range. Weekly volatility stands at 5.49%. This marks a decisive surge toward resistance, with little sign of profit-taking.

High upside probability as bull trend confronts overbought risk

For the coming week, the expected trading range is $233.00 to $256.00, keeping the forecast bracket within about ±5% of the current price and moderately below the 52-week high ($247.38) while far above the yearly low ($110.00). With all four major W1 indicators (RSI, ADX, MACD, MA-50) in strong alignment, the probability of a price increase is very high (more than 80%), while the risk of a downturn is very low. Baseline scenario sees LGND consolidating within the defined band as broad momentum signals remain bullish but overbought readings suggest resistance will hold. In a bullish scenario, a break above $247.38 could drive a challenge of $256.00. The bearish scenario involves a pullback below $233.00 if overbought signals trigger profit-taking or macro sentiment shifts.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Ligand Pharmaceuticals enhanced its oncology portfolio by investing $90 million in Athira Pharma's private placement to support the development of lasofoxifene. The current analysis signals a shift in market sentiment, highlighting the importance of monitoring Ligand’s progress on key oncology milestones as a catalyst for potential stock movements.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.